Singapore markets close in 4 hours 59 minutes
Straits Times Index
3,300.43 +7.74 (+0.24%) Nikkei
38,256.86 -17.19 (-0.04%) Hang Seng
18,116.95 +353.92 (+1.99%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,405.90 -2,763.10 (-4.59%) CMC Crypto 200
1,260.29 -78.78 (-5.88%)
ABT Jan 2026 155.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:55PM EDT. Market open.
| Previous close | 35.64 |
| Open | 35.64 |
| Bid | 39.00 |
| Ask | 44.00 |
| Strike | 155.00 |
| Expiry date | 2026-01-16 |
| Day's range | 35.64 - 35.64 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.